Arnon Kater
Amsterdam UMC · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Arnon Kater as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:04 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04639362 · CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.Stichting Hemato-Oncologie voor Volwassenen Nederland · active not recruiting · CLL · principal investigator
- Ph3NCT03836261 · Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLLAcerta Pharma BV · active not recruiting · Chronic Lymphocytic Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:04 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:04 UTC. The ranking covers the 200 most relevant of 44 PubMed records, and a shared surname and initials can bring in a namesake. All 44 on PubMed
- Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.N Engl J Med · 2018789 citationsRCR 26.9
- Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.J Clin Oncol · 2021589 citationsRCR 33.6
- Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.Lancet · 2018379 citationsRCR 12.8
- 268 citationsRCR 9.0
- First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.N Engl J Med · 2023266 citationsRCR 23.1
- Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities.NEJM Evid · 2022216 citationsRCR 15.2
- 195 citationsRCR 7.6
- 146 citationsRCR 9.9
- 141 citationsRCR 12.6
- 130 citationsRCR 12.5